Opinion|Videos|November 16, 2026

CAR T Bridging and Pirtobrutinib Triplet Therapy in CLL

The panelists discussed chimeric antigen receptor (CAR) T-cell therapy for patients with chronic lymphocytic leukemia (CLL) who have failed both covalent Bruton tyrosine kinase (BTK) inhibitors and venetoclax.

The panelists discussed chimeric antigen receptor (CAR) T-cell therapy for patients with chronic lymphocytic leukemia (CLL) who have failed both covalent Bruton tyrosine kinase (BTK) inhibitors and venetoclax. They noted that lisocabtagene maraleucel remains the only approved CAR T-cell product in this disease and that outcomes improved substantially when it was combined with ibrutinib. They described the growing use of pirtobrutinib as a bridge to reduce tumor bulk and its continuation alongside CAR T-cell therapy, noting numerically favorable real-world results but a need for prospective trials. The panelists then discussed adding pirtobrutinib to venetoclax-rituximab at relapse, which improved progression-free survival, including after covalent BTK inhibitor exposure. They weighed deeper responses against more infections, immature survival data, open-label design, and cost. Pending regulatory approval, they identified fit patients with high-risk features or bulky disease who want a fixed-duration option as strong candidates, with infection prophylaxis and vaccination before treatment.


Related to this article